Evidence map›Paper›PMID 26248380›Full record

ArticleAntimicrobial agents and chemotherapy2015

Antimicrobial Peptide Novicidin Synergizes with Rifampin, Ceftriaxone, and Ceftazidime against Antibiotic-Resistant Enterobacteriaceae In Vitro.

Odel Soren, Karoline Sidelmann Brinch, Dipesh Patel, Yingjun Liu, Alexander Liu, Anthony Coates, Yanmin Hu

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 55 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Synergistic combination of carvedilol, amlodipine, amitriptyline, and antibiotics as an alternative treatment approach for the susceptible and multidrug-resistant A. baumannii infections via drug repurposing.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023
    Article
  8. Article
  9. Article
  10. Article
  11. Prevalence of Extended-SpectrumAnimals : an open access journal from MDPI · 2022
    Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Antimicrobial Activity of Protein Fraction fromMolecules (Basel, Switzerland) · 2020
    Article
  17. Review
  18. Article
  19. Article
  20. Frontiers in microbiology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Odel SorenInstitute for Infection and Immunity, St George's, University of London, London, United Kingdom.
Karoline Sidelmann BrinchNovozymes A/S, Bagsvaerd, Denmark.
Dipesh PatelInstitute for Infection and Immunity, St George's, University of London, London, United Kingdom.
Yingjun LiuInstitute for Infection and Immunity, St George's, University of London, London, United Kingdom.
Alexander LiuJohn Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
Anthony CoatesInstitute for Infection and Immunity, St George's, University of London, London, United Kingdom.
Yanmin HuInstitute for Infection and Immunity, St George's, University of London, London, United Kingdom ymhu@sgul.ac.uk.
St George's, University of London · GBJohn Radcliffe Hospital · GBNovozymes (Denmark) · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The spread of antibiotic resistance among Gram-negative bacteria is a serious clinical threat, and infections with these organisms are a leading cause of mortality worldwide. Traditional novel drug development inevitably leads to the emergence of new resistant strains, rendering the new drugs ineffective. Therefore, reviving the therapeutic potentials of existing antibiotics represents an attractive novel strategy. Novicidin, a novel cationic antimicrobial peptide, is effective against Gram-negative bacteria. Here, we investigated novicidin as a possible antibiotic enhancer. The actions of novicidin in combination with rifampin, ceftriaxone, or ceftazidime were investigated against 94 antibiotic-resistant clinical Gram-negative isolates and 7 strains expressing New Delhi metallo-β-lactamase-1. Using the checkerboard method, novicidin combined with rifampin showed synergy with >70% of the strains, reducing the MICs significantly. The combination of novicidin with ceftriaxone or ceftazidime was synergistic against 89.7% of the ceftriaxone-resistant strains and 94.1% of the ceftazidime-resistant strains. Synergistic interactions were confirmed using time-kill studies with multiple strains. Furthermore, novicidin increased the postantibiotic effect when combined with rifampin or ceftriaxone. Membrane depolarization assays revealed that novicidin alters the cytoplasmic membrane potential of Gram-negative bacteria. In vitro toxicology tests showed novicidin to have low hemolytic activity and no detrimental effect on cell cultures. We demonstrated that novicidin strongly rejuvenates the therapeutic potencies of ceftriaxone or ceftazidime against resistant Gram-negative bacteria in vitro. In addition, novicidin boosted the activity of rifampin. This strategy can have major clinical implications in our fight against antibiotic-resistant bacterial infections.

Indexed as

AnimalsAnti-Bacterial AgentsAntimicrobial Cationic PeptidesCeftazidimeCeftriaxoneCell LineDrug Resistance, MicrobialDrug SynergismDrug Therapy, CombinationEnterobacterErythrocytesEscherichia coliFibroblastsHemolysisHumansKlebsiella pneumoniaeAnti-Bacterial AgentsAntimicrobial Cationic PeptidesCeftazidimeCeftriaxonenovicidinRifampin

Identifiers

PMID26248380
PMCPMC4576052
OpenAlexW1866981772

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.